98%
921
2 minutes
20
Background And Objectives: Extracorporeal membrane oxygenation (ECMO) provides cardiopulmonary support to over 4000 neonates and children annually worldwide. Although potentially lifesaving, ECMO carries bleeding and thromboembolic risks, often managed with platelet transfusions to maintain specific thresholds. Platelet transfusions themselves carry many risks. This survey aimed to describe stated prophylactic platelet transfusion practices among paediatric veno-arterial (VA)-ECMO providers and identify factors influencing transfusion decisions.
Materials And Methods: This is a cross-sectional electronic survey of paediatric ECMO providers from 10 centres evaluating platelet transfusion thresholds based on six patient scenarios (non-bleeding, minimally bleeding and resolved bleeding in neonates and children). Descriptive statistics were used for analysis.
Results: The survey response rate was 56% (114 of 204). Paediatric intensivists comprised 66% of respondents. The median pre-transfusion platelet count varied across VA-ECMO scenarios, with a threshold of 50 × 10/L (interquartile range [IQR] 45-75) for non-bleeding children and 70 × 10/L (IQR 50-85) for non-bleeding neonates. The threshold for minimally bleeding children, minimally bleeding neonates and resolved bleeding in children was 75 × 10/L (IQR 50-100). The threshold for resolved bleeding in neonates was 80 × 10/L (IQR 50-100). There was significant heterogeneity between and within sites (p < 0.001). Uncertainty about the level of evidence was high (59%), with clinical judgement being the most influential factor in transfusion decisions (85%).
Conclusion: Prophylactic platelet transfusion practices in paediatric ECMO vary widely, highlighting uncertainty and the need for clinical trials to improve patient outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/vox.70018 | DOI Listing |
Hematol Oncol
September 2025
Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Previous studies have shown that the pre-transplant C-reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021.
View Article and Find Full Text PDFBlood Vessel Thromb Hemost
August 2025
Department of Laboratory Medicine, University of California, San Francisco, CA.
Platelet transfusion not only attenuates bleeding and promotes hemostasis but also plays a critical role in vascular stability and endothelial barrier integrity. Under amotosalen-UVA pathogen reduction of platelets, pathogen nucleic acids undergo adduction, which prevents their replication and greatly reduces the risk of transfusion-transmitted infections. Although pathogen-reduced (PR) platelets are increasing in clinical use, the physiologic effects of pathogen reduction on platelets, particularly its impact on platelet-endothelial interactions, have yet to be described.
View Article and Find Full Text PDFCardiovasc Hematol Disord Drug Targets
August 2025
Institute of Pharmacy Training, Vietnam Military Medical University, Hanoi, Vietnam.
Introduction: Acute coronary syndrome (ACS) is a leading cause of death, and clopidogrel resistance remains a major challenge in its treatment. This study aims to determine the impact of CYP2C19 genetic variants on clopidogrel resistance (CR) and major adverse cardiovascular events (MACEs) in Vietnamese patients undergoing percutaneous coronary intervention (PCI).
Methods: We carried out a descriptive cross-sectional study, supplemented by a prospective longitudinal follow-up, on 113 ACS patients undergoing PCI with drug-eluting stent implantation at the Department of Cardiology, Military Hospital 103, from January 2015 to May 2018.
J Thromb Haemost
September 2025
Key Laboratory of Thrombosis and Hemostasis of National Health Commission, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China; Engineering Center of Hematological Disease of Ministry of Education, Cyrus Tang Hematology Center, Collaborative Innovation
Background: Megakaryocyte (MK) fragmentation into proplatelets (PPTs) and microparticles (MKMPs) is well established, yet the mechanisms underlying MKMP generation remain unclear.
Objectives: In order to investigate the role of integrin β3 and cytoskeletal dynamics during megakaryopoiesis and explore potential therapeutic targets for thrombocytopenia.
Methods: Proplatelet formation and MKMP release were evaluated both in vivo and in vitro under integrin β3 receptor impaired environment.
J Thromb Haemost
September 2025
Blood Research Institute, Versiti, Milwaukee, WI; Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI; Department of Cell biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI. Electronic address:
Background: Human platelets experience structural and functional deterioration during extra-corporeal storage at either room temperature or in the cold, impairing their reactivity and diminishing their hemostatic effectiveness following transfusion. PECAM-1 is an inhibitory receptor on platelets that exerts its inhibitory effects via phosphorylation of tyrosine residues that lie within its cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The purpose of this investigation was to attempt to restore platelet reactivity by impairing the inhibitory activity of PECAM-1.
View Article and Find Full Text PDF